Home
Resources
Publications
Preclinical Biomarkers for a Cyclin-Dependent Kinase Inhibitor Translate to Candidate Pharmacodynamic Biomarkers in Phase I Patients

Preclinical Biomarkers for a Cyclin-Dependent Kinase Inhibitor Translate to Candidate Pharmacodynamic Biomarkers in Phase I Patients

Windy Berkofsky-Fessler, Tri Q Nguyen, Paul Delmar, Juliette Molnos, Charu Kanwal, Wanda DePinto, James Rosinski, Patricia McLoughlin, Steve Ritland, Mark DeMario, Krishna Tobon, John F Reidhaar-Olson, etc.

Mol Cancer Ther. 2009 Sep;8(9):2517-25.

PMID: 19755512

Abstract:

A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is a potent cyclin-dependent kinase inhibitor with a potent antiproliferative effect at pharmacologically relevant doses and is currently in phase I clinical trials. Using preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Based on the results, eight genes (FLJ44342, CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1, and PFAAP5) were selected as dose-responsive pharmacodynamic biomarkers for phase II clinical trials.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP741713406	R547		741713-40-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: